Eloralintide Clinical Trial Results: Phase 1, 2, 3 (2026 Update)

Key facts

Phase 2 (Lancet 2025, n = 263, 48 weeks): mean weight loss 9.5% to 20.1% across doses vs 0.4% on placebo.^[2]
At 6 to 9 mg escalated, 91.1% of participants lost at least 10% of body weight.^[3]
Phase 1 (12 weeks, n = 100): up to 11.3% placebo-adjusted weight loss at 12 mg.^[5]
EloraTZP phase 2b (48 weeks, type 2 diabetes): 23.3% with eloralintide 9 mg plus tirzepatide 15 mg vs 14.8% with tirzepatide alone.^[7]
Phase 3 (ENLIGHTEN): six trials, 800 to 3,000 people each, 64-week primary endpoint, first completions estimated January to June 2028.^[10]

Eloralintide Phase 2 Results

In the 48-week phase 2 trial, eloralintide reduced body weight by 9.5% at 1 mg up to 20.1% at 9 mg, compared with 0.4% on placebo.^[2]

The trial ran at 46 US centres and enrolled 263 adults aged 18 to 75 with a BMI of 30 or more, or 27 or more with a weight-related condition, and without type 2 diabetes. Mean baseline weight was 109.1 kg and 78% were women. Results were published in The Lancet on 6 November 2025 and presented at ObesityWeek 2025.^[1]

Phase 2, week 48, efficacy estimand. Weight loss figures from Lilly; 10% responder rates from ClinicalTrials.gov.
Arm	n	Mean weight change	Lost 10% or more	Lost 5% or more
Placebo	53	-0.4%	12.9%	31.2%
1 mg	28	-9.5%	53.3%	71.6%
3 mg	24	-12.4%	60.5%	87.1%
6 mg	28	-17.6%	76.6%	85.0%
9 mg	54	-20.1%	82.3%	92.7%
6 to 9 mg (escalated)	24	-19.9%	91.1%	97.5%
3 to 6 to 9 mg (escalated)	52	-16.4%	79.2%	90.8%

Share of participants losing at least 10% of body weight at 48 weeks

Source: ClinicalTrials.gov NCT06230523 posted results.

Lilly also reports improvements in waist circumference, blood pressure, lipids, blood sugar control and inflammation markers, without publishing figures in the release.^[2] BMI fell by 3.7 kg/m2 at 1 mg up to 7.8 kg/m2 at 6 to 9 mg.^[3]

Weight loss numbers use the efficacy estimand: the result if everyone stayed on treatment. Figures from other drugs often use the treatment-regimen estimand, which counts people who stopped. Compare with care.

Eloralintide Phase 1 Results

In the 12-week phase 1 multiple-dose study, eloralintide reduced weight by up to 11.3% after placebo adjustment at 12 mg, without dose escalation.^[5]

Single dose (48 healthy adults): one dose of 12 mg reduced weight by 4.4% at week 4, against a 0.6% gain on placebo. 15 of 16 adverse events were mild.^[4]
Twelve weeks (100 adults with overweight or obesity): placebo-adjusted weight change was -2.6% at 1.2 mg, -8.9% at 3 mg, -8.5% at 6 mg and -11.3% at 12 mg.^[5]
Nausea affected 8% and vomiting 4% of eloralintide participants. Heart rate fell, by up to 14.4 beats per minute at 12 mg.^[5]
Three people on 12 mg had mood-related events and stopped treatment. The events resolved within 2 to 4 days.^[5]

Eloralintide and Tirzepatide Combination Results (EloraTZP)

EloraTZP, eloralintide 9 mg plus tirzepatide 15 mg, reduced weight by 23.3% at 48 weeks in adults with obesity and type 2 diabetes, against 14.8% with tirzepatide 15 mg alone and 3.0% with placebo.^[7]

EloraTZP phase 2b (n = 367, adults with obesity or overweight and type 2 diabetes), week 48, efficacy estimand.
Arm	Weight change	HbA1c change
Eloralintide 9 mg + tirzepatide 15 mg	-23.3%	-2.9%
Eloralintide 6 mg + tirzepatide 10 mg	-19.9%	-2.6%
Eloralintide 6 mg + tirzepatide 5 mg	-19.4%	-2.7%
Eloralintide 3 mg + tirzepatide 5 mg	-13.2%	-2.2%
Tirzepatide 15 mg alone	-14.8%	-2.4%
Eloralintide 6 mg alone	-12.3%	-1.4%
Eloralintide 9 mg alone	-11.1%	-1.3%
Eloralintide 3 mg alone	-8.2%	-1.1%
Placebo	-3.0%	-0.3%

An earlier 16-week phase 1 found that adding eloralintide 3 mg to tirzepatide 5 mg gave 17% weight loss, against 10% with tirzepatide 5 mg alone.^[6] Lilly is starting phase 3 of a single-injection EloraTZP co-formulation: AMPLIFY-1 and AMPLIFY-2, each with a 100-week primary endpoint.^[8]^[9]

EloraTZP was tested in people with type 2 diabetes, who usually lose less weight on these drugs. Its numbers cannot be lined up directly against the 48-week eloralintide trial in people without diabetes.

Eloralintide Phase 3 Trials (ENLIGHTEN)

Six ENLIGHTEN phase 3 trials are registered, enrolling 800 to 3,000 people each and measuring weight change at week 64, with the first primary completions estimated for January 2028.^[11]

From ClinicalTrials.gov records, checked 8 November 2026. Completion dates are estimates. Doses are listed only as Dose 1 to Dose 4.
Trial	Population	Size	Status	Primary completion
ENLIGHTEN-1 (NCT07321886)	Obesity or overweight, no type 2 diabetes	1,980	Recruiting	Mar 2028
ENLIGHTEN-2 (NCT07282600)	Obesity or overweight with type 2 diabetes	1,035	Recruiting	Jan 2028
ENLIGHTEN-3 (NCT07369011)	Obstructive sleep apnea with obesity	800	Recruiting	Mar 2028
ENLIGHTEN-4 (NCT07353931)	Knee osteoarthritis pain with obesity	900	Recruiting	Mar 2028
ENLIGHTEN-6 (NCT07392190)	Persistent obesity on a weekly incretin	900	Recruiting	Jun 2028
ENLIGHTEN-10 (NCT07900633)	Type 2 diabetes with raised cardiovascular risk	3,000	Not yet recruiting	Nov 2029

When Will Eloralintide Be Approved?

There is no announced approval date; with phase 3 primary completions estimated for 2028, a regulatory filing before 2028 is unlikely, and Lilly has not published a filing timeline.

As a reference point, Lilly’s retatrutide reported its first phase 3 results in December 2025^[12] and is planned for FDA submission in Q1 2027.^[13]

Frequently Asked Questions

What were the eloralintide phase 2 results?

Mean weight loss at 48 weeks was 9.5% (1 mg), 12.4% (3 mg), 17.6% (6 mg), 20.1% (9 mg), 19.9% (6 to 9 mg) and 16.4% (3 to 6 to 9 mg), against 0.4% with placebo, in 263 adults without type 2 diabetes.

How much weight did people lose on eloralintide?

Up to an average of 20.1% (21.3 kg) at 48 weeks on 9 mg in the phase 2 trial. At 6 to 9 mg escalated, 91.1% lost at least 10% of their weight.

Is eloralintide in phase 3?

Yes. Six ENLIGHTEN phase 3 trials are registered. Five were recruiting on 8 November 2026, with estimated primary completions from January 2028.

When will eloralintide be available?

Not before phase 3 finishes. The first ENLIGHTEN trials are estimated to complete in 2028, and Lilly has not given a filing date.

What were the eloralintide and tirzepatide combination results?

In a 48-week phase 2b in people with type 2 diabetes, eloralintide 9 mg plus tirzepatide 15 mg gave 23.3% weight loss, against 14.8% with tirzepatide 15 mg alone.

Sources

For research use only. Not for human or veterinary consumption. This guide summarises published research for information only. It is not medical advice and does not describe any use of products sold on this site.

Eloralintide Clinical Trial Results: Phase 1, Phase 2 and Phase 3